Grade 2 Taste Alteration, CTCAE

MedGen UID:: 293214
•Concept ID:: C1559454
•: Finding

Synonym:

CTCAE Grade 2 Taste alteration (dysgeusia)

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVGrade 2 Taste Alteration, CTCAE

Clinical finding
- Finding by Cause
  - Adverse Event
    - Adverse Event by CTCAE Category
      - Adverse Event Associated with the Gastrointestinal System
        Taste Alteration, CTCAE
        Grade 2 Taste Alteration, CTCAE

Professional guidelines

PubMed

Taste disorders following cancer treatment: report of a case series.

Epstein JB, de Andrade E Silva SM, Epstein GL, Leal JHS, Barasch A, Smutzer G
Support Care Cancer 2019 Dec;27(12):4587-4595. Epub 2019 Mar 29 doi: 10.1007/s00520-019-04758-5. PMID: 30927113

See all (1)

Recent clinical studies

Etiology

Factors for the development of anemia in patients with newly introduced olaparib: A retrospective case-control study.

Chihiro S, Hirai T, Kaneda M, Okamoto A, Kato H, Tanaka K, Kondo E, Ikeda T, Iwamoto T
Medicine (Baltimore) 2023 Jul 28;102(30):e34123. doi: 10.1097/MD.0000000000034123. PMID: 37505180 Free PMC Article

Risk factors for dysgeusia during chemotherapy for solid tumors: a retrospective cross-sectional study.

Malta CEN, de Lima Martins JO, Carlos ACAM, Freitas MO, Magalhães IA, de Vasconcelos HCA, de Lima Silva-Fernandes IJ, de Barros Silva PG
Support Care Cancer 2022 Jan;30(1):313-325. Epub 2021 Jul 20 doi: 10.1007/s00520-021-06219-4. PMID: 34283319

Taste disorders following cancer treatment: report of a case series.

Epstein JB, de Andrade E Silva SM, Epstein GL, Leal JHS, Barasch A, Smutzer G
Support Care Cancer 2019 Dec;27(12):4587-4595. Epub 2019 Mar 29 doi: 10.1007/s00520-019-04758-5. PMID: 30927113

Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns.

Moroney LB, Helios J, Ward EC, Crombie J, Burns CL, Yeo SQ, Pelecanos A, Spurgin AL, Blake C, Kenny L, Chua B, Hughes BGM
Support Care Cancer 2019 Feb;27(2):573-581. Epub 2018 Jul 17 doi: 10.1007/s00520-018-4352-5. PMID: 30019149

Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: A prospective investigation of acute swallowing and toxicity patterns.

Moroney LB, Helios J, Ward EC, Crombie J, Pelecanos A, Burns CL, Spurgin AL, Blake C, Kenny L, Chua B, Hughes BGM
Head Neck 2018 Sep;40(9):1955-1966. Epub 2018 May 13 doi: 10.1002/hed.25182. PMID: 29756244

See all (6)

Therapy

Disease and toxicity outcomes for a modern cohort of patients with squamous cell carcinoma of cutaneous origin involving the parotid gland: Comparison of volumetric modulated arc therapy and pencil beam scanning proton therapy.

Zarinshenas R, Campbell P, Sun K, Molitoris JK, Patel AN, Witek ME, Cullen KJ, Mehra R, Hatten KM, Moyer KF, Taylor RJ, Vakharia KT, Wolf JS, Ferris MJ
Radiother Oncol 2024 Apr;193:110112. Epub 2024 Feb 1 doi: 10.1016/j.radonc.2024.110112. PMID: 38309587

Factors for the development of anemia in patients with newly introduced olaparib: A retrospective case-control study.

Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: A prospective investigation of acute swallowing and toxicity patterns.

Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.

Montemurro F, Mittica G, Cagnazzo C, Longo V, Berchialla P, Solinas G, Culotta P, Martinello R, Foresto M, Gallizioli S, Calori A, Grasso B, Volpone C, Bertola G, Parola G, Tealdi G, Giuliano PL, Aglietta M, Ballari AM
JAMA Oncol 2016 Apr;2(4):445-52. doi: 10.1001/jamaoncol.2015.4720. PMID: 26720497

See all (4)